N/A N=1,164 LifeVest Safety and Efficacy in Real Life Settings in France
Sudden Cardiac Death · Left Ventricular Dysfunction · Cardiac Event
Primary: Appropriate Shock Events Per Patient — 1139; 17; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 The Effects of Intensity on Exercise-Induced Hypoalgesia During a Knee Extension Exercise
Healthy
Primary: Pressure Pain Threshold — 19.11; 48.22; -4.14 kilopascals
N/A N=28,411 Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies
Solid Organ Transplant Recipients · Autoimmune Diseases · Haematological Malignancies
Primary: The Proportion of Participants With and Without Antibodies to SARS-CoV-2 — 875; 378; 277; 1825 Participants
N/A N=72 Study Using Spray Skin Protector Versus Conventional Treatment to Prevent Acute Radiodermatitis.
Radiodermatitis · Injury, Radiation
Primary: Number of Participants Categorized by RTOG Grading Scale — 12; 6; 11; 11 Participants
Phase 3 N=256 A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)
Schizophrenia · Schizophrenia; Psychosis
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 — -20.6; -12.2 Score on a scale
Phase 2 N=1 Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
COVID 19 · SARS-CoV 2 · Pneumonia
Primary: Proportion of Subjects Alive and Off Oxygen at 14 Days — 1; 0 Participants
N/A N=149 Study to Evaluate Changes in Smokers Using on!® Nicotine Pouches
Tobacco Use
Primary: NNAL Exposure in Subjects Using Nicotine Pouches for 7 Days Versus Subjects Who Continue to Smoke Cigarettes for 7 Days — 363; 274; 312; 293 ng/g — p=<.0001
N/A N=24 Patient Actor Training to Improve HIV Services for Adolescents in Kenya
HIV/AIDS
Primary: Retention in HIV Care — 1570; 1855 Participants
N/A N=3,794 App-based Mental Health Promotion in Young European Adults
Wellbeing · Mental Disorder
Primary: Primary Outcome Measure PROMOTE Trial: Warwick-Edinburgh Mental Well Being Scale (WEMWBS) — 50.8; 51.3; 50.3 score on a scale
N/A N=40 Evaluation of the Safety and Effectiveness of ALLEVYN Gentle Border
Wound
Primary: Change in Wound Area From Baseline to End of Study Visit — 2.2 square centimeters (cm^2)
N/A N=754,745 The Incidence of Venous Thromboembolism in Atopic Dermatitis
Venous Thromboembolism · Atopic Dermatitis · Pulmonary Embolism
Primary: Number of Participants With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person. — 2576; 7563 Participants
Phase 1 N=55 A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Carcinoma, Hepatocellular · Biliary Tract Cancer · Secondary Liver Cancer
Primary: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 0; 0; 2 Participants
N/A N=10 Evaluation of Sound Processor for a Transcutaneous System
Conductive Hearing Loss · Mixed Hearing Loss
Primary: Aided Thresholds Fusion-unaided PTA — 29.6 dB
Phase 2 N=486 Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer
Metastatic Breast Cancer
Primary: 1-year Progression Free Survival — 79.4; 77.9 percentage of participants
Phase 3 N=223 Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Strongyloides Stercoralis Infection
Primary: Observed Cure Rate Against Strongyloides Stercoralis — 73.3; 89.7; 84.4; 82.8 percentage of participants